This article is more than 5 years old. Information may no longer be current.

Caprogel may reduce rebleeding rate in traumatic hyphema

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A topical medication showed a trend toward reducing the rebleeding rate in the management of traumatic hyphema in a controlled clinical study.

Dante J. Pieramici, MD, at California Retinal Consultants and colleagues across the country enrolled 51 patients with traumatic hyphema in the trial. Participants were randomized to receive a 5-day treatment with topical Caprogel (aminocaproic acid, Ista Pharmaceuticals) or a placebo gel. Follow-up was at 24 and 48 hours after treatment, and then daily throughout the trial.

Rebleeding occurred in 8% of the patients treated with Caprogel vs. 30% in the placebo group. There was a trend toward more visual improvement in the Caprogel group (54%) than in the placebo group (30%) at the last measurement. Researchers said that because the study was stopped before enrollment was complete, a larger trial will be needed to reach more definite conclusions about the drug.

Adverse events were similar in the two groups.

The study is published in the November issue of Ophthalmology.